[
  {
    "ts": null,
    "headline": "Big pharma's multiple looming patent cliffs: What to know",
    "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752267366,
      "headline": "Big pharma's multiple looming patent cliffs: What to know",
      "id": 135885558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth",
    "summary": "Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom",
    "url": "https://finnhub.io/api/news?id=70789419bc3c84dc763db0d47244f564195fdf089100efac92bab14aad4c5362",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752263576,
      "headline": "Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth",
      "id": 135883386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom",
      "url": "https://finnhub.io/api/news?id=70789419bc3c84dc763db0d47244f564195fdf089100efac92bab14aad4c5362"
    }
  },
  {
    "ts": null,
    "headline": "Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?",
    "summary": "LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.",
    "url": "https://finnhub.io/api/news?id=320c0f9f2903b2b864714b44b388f8800802721fef30a616bb68e616eb35ca08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752238440,
      "headline": "Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?",
      "id": 135883387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.",
      "url": "https://finnhub.io/api/news?id=320c0f9f2903b2b864714b44b388f8800802721fef30a616bb68e616eb35ca08"
    }
  },
  {
    "ts": null,
    "headline": "CGDV: Buy For Value, Stay For Dividend Growth",
    "summary": "CGDV: Buy For Value, Stay For Dividend Growth",
    "url": "https://finnhub.io/api/news?id=3f2a29284fda1824e0c2b24d458feb13f80c120646789b96b753521e3c2d6cc5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752235904,
      "headline": "CGDV: Buy For Value, Stay For Dividend Growth",
      "id": 135882203,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3f2a29284fda1824e0c2b24d458feb13f80c120646789b96b753521e3c2d6cc5"
    }
  },
  {
    "ts": null,
    "headline": "Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts",
    "summary": "Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click here to find out why TERN is a Buy.",
    "url": "https://finnhub.io/api/news?id=368947792f663051618f16e0e68054efbc23a017ccbe307868ab1042f9a00f79",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752233264,
      "headline": "Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts",
      "id": 135880943,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196074525/image_2196074525.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click here to find out why TERN is a Buy.",
      "url": "https://finnhub.io/api/news?id=368947792f663051618f16e0e68054efbc23a017ccbe307868ab1042f9a00f79"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: The Market Doesn't Get It",
    "summary": "Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimerâs trial, offers significant long-term upside. Click here to read an analysis of NVO stock now.",
    "url": "https://finnhub.io/api/news?id=0dadeac5ca3a61b4068e062da8213cf35cec9e3882d638456818a2b3832ba73d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752231352,
      "headline": "Novo Nordisk: The Market Doesn't Get It",
      "id": 135880039,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153927815/image_2153927815.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimerâs trial, offers significant long-term upside. Click here to read an analysis of NVO stock now.",
      "url": "https://finnhub.io/api/news?id=0dadeac5ca3a61b4068e062da8213cf35cec9e3882d638456818a2b3832ba73d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and : Our 2024 Sustainability Report PDF (2024 SustainabilityReport Final)",
    "summary": "2024 Sustainability Report Table of Contents A Message from Our CEO 3 Sustainability Highlights 4 Our Strategy ...",
    "url": "https://finnhub.io/api/news?id=93a17b0fa60d4f15378dbd4959ed204eaeba9fb0df0b3bf605e868e59496b6a4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752226148,
      "headline": "Eli Lilly and : Our 2024 Sustainability Report PDF (2024 SustainabilityReport Final)",
      "id": 135877662,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "2024 Sustainability Report Table of Contents A Message from Our CEO 3 Sustainability Highlights 4 Our Strategy ...",
      "url": "https://finnhub.io/api/news?id=93a17b0fa60d4f15378dbd4959ed204eaeba9fb0df0b3bf605e868e59496b6a4"
    }
  },
  {
    "ts": null,
    "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
    "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
    "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220860,
      "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
      "id": 135876885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
      "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.",
    "summary": "The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.",
    "url": "https://finnhub.io/api/news?id=e6b663a242acdabc7cbd8b56cfe95bc822c6f6a073bcfb8740e38f53b68a8d2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220800,
      "headline": "Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.",
      "id": 135872906,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.",
      "url": "https://finnhub.io/api/news?id=e6b663a242acdabc7cbd8b56cfe95bc822c6f6a073bcfb8740e38f53b68a8d2c"
    }
  },
  {
    "ts": null,
    "headline": "FDRR: Look At FCPI Instead",
    "summary": "FDRR focuses on large-cap dividend stocks tied to Treasury yields but has lagged peers like FCPI despite solid dividend growth. Check out why FDRR ETF is a hold.",
    "url": "https://finnhub.io/api/news?id=387ca8eaad7512d74bc619ea0ab0ede13f23ce7df8ca01ec198d4c3d7200f2de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752218666,
      "headline": "FDRR: Look At FCPI Instead",
      "id": 135874479,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1551007220/image_1551007220.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "FDRR focuses on large-cap dividend stocks tied to Treasury yields but has lagged peers like FCPI despite solid dividend growth. Check out why FDRR ETF is a hold.",
      "url": "https://finnhub.io/api/news?id=387ca8eaad7512d74bc619ea0ab0ede13f23ce7df8ca01ec198d4c3d7200f2de"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Co (India) with Association of Physicians of India announces launch of API - Obesity Gurukul - statement",
    "summary": "Eli Lilly and Co:* Eli Lilly and Co with Association of Physicians of India announces launch of API - Obesity Gurukul - statement...",
    "url": "https://finnhub.io/api/news?id=ea87ea163f017f19e5a79a71601f91375f9de099e6b556524c7ed9cb998277e8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752201737,
      "headline": "Eli Lilly and Co (India) with Association of Physicians of India announces launch of API - Obesity Gurukul - statement",
      "id": 135867880,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co:* Eli Lilly and Co with Association of Physicians of India announces launch of API - Obesity Gurukul - statement...",
      "url": "https://finnhub.io/api/news?id=ea87ea163f017f19e5a79a71601f91375f9de099e6b556524c7ed9cb998277e8"
    }
  }
]